Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo
for the treatment of spasticity in subjects with multiple sclerosis (MS).